Chat with MASLD AI
Hi, I am MASLD AI.
Suggested Questions :
MASLD AI 06:48 AM
November 2025
In this high-yield session, HoChong Gilles, NP from the Central Virginia VA Healthcare System, guides viewers through a practical approach to abnormal liver imaging and the challenge of incidental liver lesions. She reviews how to differentiate cystic versus solid liver lesions, outline key risk factors, and interpret enhancement patterns on ultrasound, CT, and MRI to distinguish benign findings—such as simple cysts, hemangiomas, FNH, and hepatic adenomas—from malignant lesions including hepatocellular carcinoma (HCC) and metastatic disease. Designed for APPs and clinicians who frequently encounter unexpected lesions on imaging, this concise overview provides clear strategies for knowing when to reassure, when to monitor, and when to escalate evaluation or referral.
Related Webcast
Webcast: Lifestyle Management With Erin Parkinson
July 2025
In this impactful session from the GHAPP MASLD Community Network, Erin Parkinson, APRN, explores the vital role of lifestyle modifications in the management of MASLD (Metabolic dysfunction-associated steatotic liver disease) and MASH (Metabolic dysfunction-associated steatohepatitis). Through the lens of a real-world case study, Erin illustrates how clinical tools like FIB-4 and FibroScan® can be used to assess fibrosis risk and guide interventions for patients presenting with metabolic syndrome and hepatic steatosis. With a focus on practical, personalized care, this presentation highlights how diet, exercise, and culturally sensitive counseling can meaningfully reduce hepatic fat, inflammation, and fibrosis—key factors in preventing progression to cirrhosis or hepatocellular carcinoma. Erin discusses the impact of processed foods, high-fructose corn syrup, and sedentary behavior, while offering actionable guidance on introducing Mediterranean diets, intermittent fasting, and realistic exercise goals tailored to individual readiness and barriers. Whether you're a hepatology specialist, primary care provider, or obesity medicine clinician, this talk delivers tools to better support patients with MASLD/MASH through sustainable behavioral change and longitudinal follow-up.
Watch Now
Webcast: MASLD vs MetALD With Alison Moe
November 2025
In this insightful session, Alison Moe, PA-C, from Atlantic Gastroenterology Associates, a division of United Digestive, breaks down how to distinguish metabolic-associated steatotic liver disease (MASLD) from MetALD—the overlap of metabolic dysfunction and alcohol-related liver injury. Using a real-world case study, Alison highlights how small amounts of daily alcohol intake can significantly accelerate fibrosis in patients with metabolic risk factors like PCOS, hypertension, and dyslipidemia. She explains how to interpret FibroScan (kPa/CAP) results, evaluate PEth testing for alcohol exposure, and determine when therapies such as Resmetirom are appropriate. This discussion emphasizes practical strategies for counseling patients on alcohol cessation, lifestyle modification, and fibrosis monitoring, helping clinicians better identify and manage those at risk for advanced liver disease.
Watch Now
Live From GHAPP National: Abnormal Liver Chemistry Workup
November 2025
In this session, Jeremy Davis, ACNP from Shreveport, Louisiana, breaks down a practical, step-by-step approach to evaluating abnormal liver chemistries. Using a real patient case, he reviews how to interpret ALT, AST, ALP, bilirubin, MCV, and GGT patterns; when to suspect hepatocellular, cholestatic, or mixed injury; and how to build an efficient differential using history, medications, alcohol assessment, and key labs (viral hepatitis panel, autoimmune markers, iron studies, Wilson disease testing, alpha-1 antitrypsin phenotype). He also highlights the role of ultrasound, MRCP, non-invasive fibrosis tests (FIB-4, ELF, VCTE), and when biopsy is needed. A practical, clinic-ready guide for APPs and clinicians assessing elevated liver enzymes and differentiating MASLD, alcohol-related disease, DILI, and other common etiologies.
Watch Now
Webcast: MASLD vs MetALD With Allysa Saggese
September 2025
In this MASLD Community Network session, Allysa Saggese, NP, from Weill Cornell Medicine, New York, walks through a real-world case to demystify the overlap between MASLD, MASH, and metabolic-alcohol related liver disease (MetALD). You’ll learn how to take a precise alcohol history, translate “standard drink” equivalents (≈14 g ethanol), and use objective biomarkers like PEth alongside FIB-4, FibroScan (kPa), ELF, CAP, and MRI elastography to stage disease accurately and catch discordant results. Allysa covers how alcohol can skew labs (ALT/AST, triglycerides, BP), why reducing/abstaining may change non-invasive testing thresholds, when to consider liver biopsy, and who qualifies for HCC surveillance. She also outlines treatment pillars—lifestyle optimization, cardiometabolic risk control, and appropriate pharmacotherapy (including where resmetirom fits and when to avoid it)—so clinicians can tailor care for patients spanning pure MASLD to MetALD. Watch to sharpen your staging, counseling, and monitoring strategy—and help patients make data-driven changes that improve outcomes.
Watch Now
Webcast: MASLD Basics With Scott Springer
August 2025
Welcome to the GHAPP MASLD Community Network, where Scott Springer, PA-C, from Erie County Medical Center in Buffalo, NY, provides a comprehensive overview of the evolving landscape of steatotic liver disease. Sponsored by Madrigal Pharmaceuticals, this session breaks down the recent nomenclature shift from NAFLD/NASH to MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) and MASH (Metabolic Dysfunction-Associated Steatohepatitis). Scott explores how overlapping etiologies like alcohol-associated liver disease (ALD) and the emerging classification of MetALD better reflect real-world patient populations. Learn about key diagnostic strategies—including the use of FIB-4, ELF score, and transient elastography—to assess fibrosis risk and guide referral to hepatology care. With a clinical case study, Scott highlights the importance of accurate staging, ruling out alternative etiologies, and understanding progression rates in high-risk patients. This session is a must-watch for GI and hepatology APPs looking to stay updated on guidelines, non-invasive diagnostics, and best practices for managing MASLD/MASH in primary and specialty settings.
Watch Now
Webcast: MASLD Pharmacotherapy With Summer Collier
August 2025
Join Summer Collier, FNP, from UC San Diego Health, for a comprehensive discussion on pharmacotherapy for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and MASH, presented through the GHAPP MASLD/MASH Community Network and sponsored by Madrigal Pharmaceuticals. In this session, Summer outlines the foundational role of lifestyle modification in treating MASLD, including diet, exercise, and weight loss, while emphasizing the growing need for liver-directed therapies in patients with moderate to advanced fibrosis. She reviews the clinical use of GLP-1 receptor agonists such as semaglutide and tirzepatide, which aid in glycemic control and significant weight loss, and explores their application in hepatology—including key data showing MASH resolution and fibrosis improvement. The discussion also addresses older treatment options like vitamin E and pioglitazone, explaining their risks, limitations, and patient selection criteria. The highlight of the presentation is a detailed analysis of resmetirom (Rezdiffra)—the first FDA-approved therapy for non-cirrhotic NASH with F2–F3 fibrosis. Summer walks through the MAESTRO-NASH trial, covering the mechanism of THR-β activation, improvements in liver histology, safety data, and practical prescribing guidance, including non-invasive monitoring, statin dose considerations, and drug–drug interactions. The session concludes with expert insights on staging, treatment duration, insurance access, and the evolving future of MASLD therapy. A must-watch for hepatology, GI, and primary care providers seeking to implement the latest evidence-based approaches in managing fatty liver disease.
Watch Now
Webcast: Comparing F3 and F4 Fibrosis With Lindsay Pratt
July 2025
Join Lindsay Pratt, PA-C from the University of Colorado Liver Transplant Program, for an in-depth clinical comparison of F3 and F4 fibrosis in patients with MASLD (Metabolic Dysfunction–Associated Steatotic Liver Disease) and MASH (Metabolic Dysfunction–Associated Steatohepatitis). Using an identical patient profile with differing non-invasive testing results, Lindsay demonstrates how to accurately stage fibrosis using tools like FIB-4, FibroScan, CAP score, and ELF test—emphasizing when pharmacologic intervention is appropriate and when advanced monitoring becomes critical. This session explores the clinical implications of fibrosis staging, treatment pathways including resmetirom (Rezdiffra), the role of GLP-1 receptor agonists, and practical nutrition and lifestyle strategies. For F4 patients, Lindsay outlines key elements of surveillance for hepatocellular carcinoma (HCC), portal hypertension management, and transplant evaluation. Whether you're in hepatology or primary care, this case-based discussion offers evidence-backed guidance for managing patients across the MASLD/MASH spectrum and preventing liver disease progression.
Watch Now
Webcast: Comparing F3 and F4 Fibrosis With Edith Johannes
July 2025
Join Edith Johannes, NP from UCLA Health, for a comprehensive and approachable introduction to MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)—formerly known as NAFLD—and how to accurately diagnose it. Designed for primary care providers and early learners in hepatology, this session outlines the fundamental criteria for diagnosing MASLD and MASH, the importance of ruling out alternate causes of hepatic steatosis, and the key role of cardio-metabolic risk factors. Edith discusses how to apply non-invasive testing tools such as the FIB-4 score, ELF test, and elastography to determine fibrosis stage, along with guidance on when to consider liver biopsy and refer to hepatology. The presentation also explores the overlap between MASLD and alcohol-related liver disease, addresses the impact of genetic risk factors like PNPLA3 (particularly in Hispanic populations), and reinforces the urgent need for early detection to prevent cirrhosis and liver cancer. With clinical pearls and case-based examples, this session helps clinicians feel confident in evaluating patients for MASLD and navigating next steps for care.
Watch Now
Webcast: MASLD vs MetALD With Oyin Penny
October 2025
In this educational session, Oyin Penny, FNP, from Premier Gastroenterology of Kansas City, discusses the overlap between MASLD and MetALD, highlighting how metabolic risk factors and alcohol intake accelerate liver injury and fibrosis. Presented through the GHAPP MASLD Community Network and supported by Madrigal Pharmaceuticals, this talk uses a real-world case study to explain diagnostic tools like FibroScan, CAP score, and PEth testing, along with clinical criteria for distinguishing MASLD, MetALD, and ALD. Key management strategies include Mediterranean diet, weight loss, alcohol abstinence, and monitoring for advanced fibrosis and HCC risk.
Watch Now
Webcast: MASLD vs MetALD With Scott Springer
October 2025
In this educational session, Scott Springer, PA-C, from Erie County Medical Center, discusses the intersection of Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) and MetALD—a condition involving both metabolic dysfunction and alcohol-related liver injury. Presented through the GHAPP MASLD Community Network and supported by Madrigal Pharmaceuticals, this talk highlights diagnostic challenges, alcohol-use quantification, and the importance of objective biomarkers like PEth testing for accurate classification. Using a real patient case, Scott explains how metabolic risk factors and alcohol intake synergistically accelerate fibrosis, and how clinicians can apply non-invasive tests (FibroScan, ELF, FIB-4) and counseling strategies to improve patient outcomes.
Watch Now